



CECOG ACADEMY

Central European Cooperative Oncology Group



**THORACIC
CANCERS
ACADEMY**

5th THORACIC CANCERS ACADEMY

**4. – 5. April
2025**



**Sheraton
Novi Sad, Serbia**

Scientific Committee

Christoph Zielinski (Austria)
Christiane Thallinger (Austria)
Bojan Zarić (Serbia)
Tanja Čufer (Slovenia)

www.cecog.org



Friday, 4 April, 2025

13:00 – 13:10	Welcome Session
13:10 – 14:00	Welcome Words by <i>B. Zarić, Novi Sad</i> <i>C. Zielinski, Vienna</i>
	News in screening and staging
	Chair J. Djekic, Novi Sad Chair C. Zielinski, Vienna Lung cancer screening - where are we exactly? – <i>T. Blum, Göttingen</i> <hr/> Overview of TNM 9 - lung cancer, pleural mesothelioma and thymic malignancies - <i>E. Talakić, Graz</i> <hr/>
	14:00 – 14:30 Industry Symposium by Amicus See pg. 5
	<i>Coffee Break 14:30 – 14:40</i>
14:40 – 15:55	Resectable NSCLC – rapidly changing treatment paradigms
	Chair M. Jakopovic, Zagreb Chair J. But Hadzic, Ljubljana Surgery for resectable NSCLC – when and what? – <i>MA. Hoda, Vienna</i> <hr/>
	SBRT for operable and inoperable NSCLC – <i>J. But Hadzic, Ljubljana</i> <hr/>
	Perioperative systemic treatment for resectable NSCLC (Online) – <i>T. Čufer, Ljubljana</i> <hr/>
	15:55 – 16:55 Industry Symposium by Astra Zeneca See pg. 5
	<i>Coffee Break 16:55 – 17:05</i>

Friday, 4 April, 2025

17:05 - 17:55	Locally advanced and advanced NSCLC
	Chair T. Ciuleanu, Cluj-Napoca Chair B. Zarić, Novi Sad
	Histology and molecular pathology of NSCLC – <i>I. Kern, Golnik</i>
	Treatment of non-oncogene-addicted advanced NSCLC – <i>B. Zaric, Novi Sad</i>
	17:55 – 18:25 Industry Symposium by MSD See pg. 5
	<i>Coffee Break 18:25 – 18:35</i>
18:35 – 19:25	Palliative and supportive care in metastatic lung cancer
	Chair E. Talakić, Graz Chair I. Kuhjada, Novi Sad
	Interventional bronchoscopy options for palliative patients – <i>A. Rozman, Golnik</i>
	Optimal supportive therapy in lung cancer patients – <i>T. Kovacevic, Novi Sad</i>
	<i>Welcome Reception 19:30 – 20:30</i>

Saturday, 5 April, 2025

09:00 – 10:15	Pleural Mesothelioma – whats new?
	Chair MA. Hoda, Vienna
	Chair M. Jakopovic, Zagreb
	Update on histology and molecular pathology in PM – <i>Luka Brcic, Graz</i>
	The current role of radiation in PM – <i>T. Boskovic, Novi Sad</i>
	Systemic options including IO in PM – <i>M. Jakopovic, Zagreb</i>
	10:15 – 11:15 Industry Symposium by Pfizer See pg. 6
	<i>Coffee Break 11:15 – 11:30</i>
11:30 – 12:10	Young oncologists MDT Session (bring your case to discuss with the experts)
	Panellist B. Zarić, M. Jakopovic, J. But Hadzic, L. Brcic
	During this session, participants will present their cases, which will be followed by an engaging discussion with all attendees and faculty members.
	<i>Coffee Break 12:10 – 12:25</i>
12:25 – 13:40	SCLC and Thymic Malignancies
	Chair Luka Brcic, Graz
	Chair D. Radosavljevic, Belgrade
	Biomarkers in SCLC – <i>is there any progress – J. Moldvay, Budapest</i>
	Systemic treatment of SCLC (including novel approaches) – <i>J. Spasic, Belgrade</i>
	Thymic Malignancies: Current standards in treatment (Online) – <i>S. Plestina, Zagreb</i>
13:40 – 14:10	Keynote Lecture
	Chair B. Zarić, Novi Sad
	Tracing Cancer Diagnosis and Treatment – an Overview over 1.7 Million Years – <i>C. Zielinski, Vienna</i>
14:10 – 14:20	Closing and Farewell
	<i>C. Zielinski, Vienna</i> <i>B. Zarić, Novi Sad</i>



Notes





Industry Symposia | Friday, 4 April, 2025



14:00 – 14:30	Innovations in Lung Cancer Treatment: Insights from CheckMate 9LA and CheckMate 816 Amicus
	CheckMate 816: The role of Nivolumab and Chemotherapy in the Neoadjuvant Treatment of NSCLC – <i>Prof. Dr. Bojan Zaric, Institute for Pulmonary Diseases of Vojvodina</i>
	CheckMate 9LA: Combining Nivolumab and Ipilimumab and limited Chemotherapy in Advanced Lung Cancer – <i>Dr. Jelena Spasic, Institute for Oncology and Radiology Serbia</i>



15:55 – 16:55	Navigating the advanced lung cancer treatment landscape: addressing hard-to-treat patients AstraZeneca
	Welcome and introductions – <i>Prof. Dr. Bojan Zarić (Moderator)</i>
	Overcoming limitations with first-line immunotherapy in mNSCLC – <i>Marko Jakopović / Izidor Kern / Tanya Zlatanova (Panel)</i>
	Metastatic EGFRm NSCLC: re-defining possibilities through emerging therapies – <i>Marko Jakopović / Izidor Kern / Tanya Zlatanova (Panel)</i>
	Improving outcomes for patients with SCLC – today and tomorrow – <i>Marko Jakopović / Izidor Kern / Tanya Zlatanova (Panel)</i>



17:55 – 18:25	Key to better outcomes in the treatment of non-small cell lung cancer
	<i>Prof. Dr. Bojan Zaric, Institute for Pulmonary Diseases of Vojvodina</i>
	<i>Dr. Jelena Spasic, Institute for Oncology and Radiology of Serbia</i>



Industry Symposia | Saturday, 5 April, 2025



ALK Positive Metastatic NSCLC; Recent Advances and Patient Outcome Optimisation | Pfizer Oncology

Chair B. Zarić, Novi Sad

Treatment Options for 1st Line ALK Positive mNSCLC: An Overview of Recent Clinical Data
– Prof. Dr. Marko Jakopović, University Hospital Centre Zagreb, Croatia

Optimising Treatment Outcomes for ALK Positive mNSCLC Patients: When & How
– Dr. Abed Agbarya, Bnei Zion Medical Center, Israel

Optimal First-Line Therapy Selection for ALK Positive mNSCLC – Prof. Dr. Thorsten Fuereder, University Hospital Vienna, Austria

Panel Discussion

10:15 – 11:15



MEETING VENUE

Sheraton Novi Sad

Polgar Andraša 1 | 21000 Novi Sad | Serbia

FINANCIAL SUPPORT AND SPONSORS

We kindly thank the following sponsors for their support
of the **5th CECOG Thoracic Cancers Academy**

Gold Sponsors



Silver Sponsors



CECOG Academy
Central European Cooperative Oncology Group

Organisation

Wiener Medizinische Akademie GmbH
Alser Strasse 4 • 1090 Vienna, Austria

[t] +43 1 405 1383 39

[e] cecog@wma.co.at

www.cecog.org

CECOG ACADEMY



© all rights reserved by the Central European Cooperative Oncology Group